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Background: Human papillomavirus (HPV) is often present in oropharyngeal cancers. Head and neck tumors have
been examined for other molecular markers including p53 and annexin A1 (ANXA1). Here, we investigated the
prevalence of HPV and its relationship with p53 and ANXA1 in patients with oropharyngeal cancer.
Methods: We have analyzed tumor and adjacent mucosa from 22 patients with squamous cell carcinoma of the
oropharynx in addition to samples of the oropharyngeal epithelium in subjects without cancer. We evaluated the
presence of the HPV (subtypes 16/18 and 31/33) by chromogenic in situ hybridization. Additionally, we used
immunofluorescence to examine the expression of p16, p53, ANXA1 and the phosphorylation of the ANXA1
residues Ser27 (ANXA1-SER) and Tyr21 (ANXA1-TYR).
Results: We have detected the presence of HPV genome in 59% of the 22 tumors. Of those, 92% were also positive
for p16 immunostaining. Furthermore, we demonstrated a reduction in the expression of p53 in HPV + compared
to HPV- tumors. Also, a reduction was observed in the expression of ANXA1 in tumors compared to epithelium
from the margins and from controls. We also noted a reduction in ANXA1-TYR in tumors. However, the expression
of both ANXA1 and ANXA1-SER were elevated in the margins of the HPV + versus HPV- tumors.
Conclusions: Our results confirm a high prevalence of HPV in oropharyngeal cancer and a reduction in p53
expression in HPV + tumors. We observed a hypoexpression of ANXA1 and ANXA1-TYR in oropharyngeal cancer.
The increase in ANXA1-SER in the margins of HPV + tumors suggests that the epithelium in these cases had been
activated by an infectious agent. Those findings indicate that ANXA1 and its phosphorylated forms can play important
roles in the response to HPV infection and the carcinogenesis of the oropharynx.
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Cancers of the head and neck are a global health prob-
lem. These tumors occur frequently, especially among
low-income populations, with a high social cost because
of the associated morbi-mortality. Annually, this path-
ology affects approximately 633,000 people worldwide
causing 325,000 deaths [1]. The main risk factors are smok-
ing and consumption of alcohol [2]. However, a group of
patients exists that lack these precursors, leading to the sus-
picion that other factors might play important roles in the* Correspondence: cleberson.queiroz@liverpool.ac.uk
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unless otherwise stated.process of carcinogenesis in this region [3,4]. The discovery
of biomarkers that could ultimately translate into prognos-
tic or predictive tools as well as possible new drug targets
is, therefore, an important medical need.
Cancer of the oropharynx stands out from other topog-
raphies in the head and neck region due to its strong asso-
ciation with the infection caused by human papillomavirus
(HPV). Currently, possible changes to the therapeutic ap-
proach based on HPV status are under discussion because
of evidence suggesting that the presence or absence of the
virus leads to distinct biological mechanisms and behaviors
of the tumor [5]. HPV is an epitheliotropic virus associ-
ated with several cutaneous and mucosal pathological
conditions, both benign and malignant. Various studies
have demonstrated the presence of high-risk carcinogenicl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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substantial proportion of these tumors [6]. Recent
studies have shown high infection rates through the
demonstration of the presence of viral genome [5,7,8]
or using immunostaining directed to p16, a protein
known to be upregulated in the presence of high-risk
HPVs and frequently used as a surrogate of HPV infec-
tion [7,9,10].
Tumor suppressor protein p53 has several functions
that are related to maintaining genomic stability and
inhibiting cell proliferation in response to DNA damage.
For preventing neoplasias to occur, the most important
of these functions are cessation of cell growth [11,12]
and induction of either apoptosis [13,14] or senescence
[15,16]. P53 performs these functions both by acting as a
transcription factor (inhibiting or stimulating the tran-
scription of specific genes) and by acting directly on
various elements of the regulatory machinery of the
cell cycle [17]. Under normal conditions, the protein is
expressed only in small quantities and with a very short
half-life (only few minutes) and is normally undetect-
able by methods such as immunofluorescence. When
mutated or inactivated, it becomes unable to impede
the progression of the carcinogenic process and begins
to accumulate in cells and, thus, can be easily identifi-
able [18].
Annexin-A1 (ANXA1) is a 37-kDa protein that is
present in various cell types and belongs to the annexin
family (proteins that share the capacity to bind in a
calcium-dependent manner with the phospholipids that
are present in negatively charged membranes) [19].
Evidence indicates that ANXA1 participates in signal
transduction [20], in inflammation [19,21-23], in control-
ling cell growth and apoptosis [24,25], and in endocytosis
[26], among other functions. In addition to the general
properties attributed to ANXA1, post-translational
changes such as phosphorylation are known to have an
important influence on the activities performed by this
protein [27-31].
Various types of cancers induce a differential expres-
sion of ANXA1. In breast cancer, the loss of ANXA1 ex-
pression is associated with poorer global survival rates
[32]. In patients with gastric cancer, evidence shows that
the loss of ANXA1 is associated with tumor progression,
lymph node metastases, and poor prognosis [33]. A re-
duction in ANXA1 expression has been found in pros-
tate cancer compared to non-tumor tissue [34]. On the
other hand, an elevated expression of ANXA1 has been
demonstrated in hepatocellular cancer [35], pancreatic
cancer [36], glial tumors [37], and even in breast cancer
[38], reinforcing the contradictory findings to date. In
adenocarcinomas of the esophagus and the esophagogas-
tric region, the hyperexpression of ANXA1 is associated
with a poorer prognosis than that for tumors of thishistology with a low expression of the protein [39].
Evidence indicates that ANXA1 that is phosphory-
lated at the tyrosine 21 residue (ANXA1-TYR) is
present in higher levels in cervical cancer than in nor-
mal tissues [27].
Based on the data described above, our hypothesis is
that ANXA1 and its phosphorylated forms could be dif-
ferentially expressed in oropharyngeal cancer and that a
relationship might exist between its expression, the ex-
pression of p53 and the presence of HPV infection.
Therefore, we evaluated the presence of HPV infection
(serotypes 16/18 and 31/33) in samples of squamous cell
carcinoma of the oropharynx and analyzed the expres-
sion, through immunofluorescence (IF), of p16, p53,
ANXA1 and two phosphorylated forms of ANXA1 (at
specific serine and tyrosine residues). Based on the re-
sults that we obtained, we assessed the potential rela-
tionship among these markers.
Results
Histopathological tumor analysis
The evaluation of the tumors with hematoxylin and eosin
staining confirmed that all the cases consisted of squamous
cell carcinomas. In the tumor samples analyzed, we ob-
served 5 (22.7%) well-differentiated, 6 (27.3%) moderately
differentiated, and 10 (45.5%) poorly differentiated carcin-
omas. One (4.5%) of the samples was very small and did
not allow for histological grading. No significant relation-
ship was observed between the level of ANXA1 expression
and the grade of tumor differentiation.
Characterization of the presence of HPV and the
expression of p16 and p53
The analysis of HPV infection by CISH (Figure 1) indi-
cated the presence of the viral DNA in 13 (59.1%) pa-
tients. All of the HPV + cases showed positivity for the
probe combination targeting serotypes 16/18 (meaning
that these samples might be positive for HPV16, HPV18
or both). Two cases were positive for both the 16/18
probe mix and the 31/33 probe mix, while no cases were
positive for the 31/33 probe mix alone. Among the HPV+
cases, the proportion of males was 61%, whereas in the
HPV- group, 100% of the cases were males (p = 0.05). We
did not observe significant differences in terms of age and
the presence of the risk factors of smoking and drinking be-
tween HPV+ and HPV- groups (Table 1). None of the 9
HPV-negative carcinomas (based on CISH) showed positive
staining for p16 through IF. On the other hand, 12 out of
13 HPV-positive samples were positive for p16 staining
(92.3%). Therefore, we used the CISH-positive set for the
comparisons with the other markers.
Using IF (Figure 2), we analyzed the nuclear expres-
sion of the p53 protein in 21 of the 22 samples (one
HPV + case did not undergo this analysis for technical
Figure 1 Chromogenic in situ hybridization for detection of HPV 16/18. A) Positive control (CasKi cells, magnification: 600x); B) Negative
cancer sample (400x); C) Positive cancer sample (400x).
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7 (33.3%) of the 21 samples. Of the 12 HPV + samples
that were tested for p53, only 2 (16.6%) expressed p53,
while of the 9 HPV- samples, 5 (55%) expressed the pro-
tein (p < 0.001).
Analysis of ANXA1 expression in oropharyngeal cancer
We initially analyzed ANXA1 expression on the epithelial
margin of the tumors and in the epithelia of the non-
neoplastic controls, and we did not observe any significant
differences between the groups. We then made compari-
sons between the tumor tissues and both groups of epithe-
lia (margins and non-neoplastic controls) (Figure 3). In
addition, we analyzed the expression of ANXA1 according
to the status of p53 (p53+ vs. p53-) and the presence or ab-
sence of HPV. We observed a global reduction in the ex-
pression of ANXA1 in the neoplastic tissues compared to
that in the epithelia of both margins and controls (Table 2).
This ANXA1 hypoexpression in the tumors was evident in
both the HPV+ and HPV- cases, except in the group of
HPV- and p53- tumors. Analysis of ANXA1 expression in
the epithelial margins revealed an increase in ANXA1
expression in HPV+ cases compared to that in the HPV-
cases and the non-neoplastic controls. We found no signifi-
cant difference in ANXA1 expression between p53+ and
p53- tumors or between HPV+ and HPV- tumors.
To better understand the role of ANXA1 in cancer of
the oropharynx, we evaluated the expression of itsTable 1 Patient characteristics according to HPV status
Characteristics HPV+ HPV- p-value
Age ns
Average 53.1 56.9




Smoking 86% 100% ns
Alcohol consumption 29% 50% ns
ns = not significant.phosphorylated forms in the tissues studied (Table 3).
The expression of ANXA1-SER was similar between the
tumors and the epithelia in the HPV- samples. However, in
the HPV+ cases, we noted an increase in its expression in
the margin compared to the expression in both the neo-
plastic tissue and the controls. Expression of ANXA1-SER
was similar between HPV+ and HPV- groups.
In contrast, the analysis of ANXA1-TYR expression re-
vealed a significant reduction in cancerous tissues com-
pared to the margin epithelium in both the HPV+ and
HPV- cases. No differences were observed in the expression
of ANXA1-TYR between the HPV+ and HPV- groups.
Discussion
Our results have indicated presence of HPV in 59.1% of
the cases of oropharyngeal cancer that were examined;
this finding is similar to those reported in recently pub-
lished studies [5,8]. It confirms the notion that viral
DNA is often present in this pathology, independent of
the geographical area studied. In all cases in which HPV
was detected, the probe mix targeting serotypes 16 and
18 was positive. Since several studies have shown that
HPV 16 is responsible for more than 90% of HPV-
related oropharyngeal cancers [8,40], it is highly likely
that the majority of our cases are linked HPV16.
We have noticed a reduced expression of ANXA1 in
oropharyngeal cancer compared to the expression ob-
served in the epithelium of the tumor margin and in the
non-neoplastic controls, a finding that is in agreement with
the majority of studies focusing on cancers of the head and
neck. This pattern was observed both in HPV+ cases and
HPV- cases in which p53 was expressed. In the group that
tested negative for both HPV and p53, no difference was
observed in the expression of ANXA1 between the tumor
and the normal epithelium. However, the absence of signifi-
cant difference between these cases may be due to the
limited sample size.
ANXA1, a protein related to inflammatory response and
involved in cell proliferation, has been studied in various
cancers with contrasting findings. In tumors of the head
and neck area, studies have been done evaluating the role
Figure 2 Nuclear expression of the p53 protein in oropharyngeal cancer. A) HPV-positive cancer sample exhibiting absence of p53
immunofluorescence. B) HPV-negative cancer sample exhibiting nuclear fluorescence denoting expression of the accumulated protein in
tumor tissue. Magnification: 400x.
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prognosis. In one study, researchers analyzed various pro-
teins with potential to be biomarkers for differentiation
and prognosis in patients with nasopharyngeal cancer
[41]. The authors identified 36 proteins with differentiated
expression between normal epithelium of the nasopharynxFigure 3 Expression of ANXA1 protein. A) Epithelial adjacent margin. B)
(blue) to enable architectural definition. Right: same sections as in left, show
of ANXA1 in B (right) compared to its stromal tissue and to normal epitheland nasopharyngeal carcinoma. Of these proteins, only 3
were considered to be potential biomarkers for carcin-
omas: stathmin (increased expression), 14-3-3ϭ (reduced
expression), and ANXA1 (reduced expression). Various
other studies have corroborated these findings, showing
a reduction of ANXA1 expression in squamous cellOropharyngeal squamous cell carcinoma. Left: nuclei stained by DAPI
ing cytoplasmic ANXA1 expression (green). Note the lower expression
ium in A (right). Magnification: 200x.
Table 2 Expression of ANXA1 according to HPV and p53 status
HPV+ HPV-
p53+ p53- p53+ p53- Controls
Cancer 47.3 ± 2.7* 55.4 ± 5.7* 46.4 ± 4.5* 53.4 ± 3.0 -
Epithelium 105.0 ± 2.9## 107.5 ± 4.3### 79.2 ± 3.7 62.5 ± 2.5 82.3 ± 1.5
We quantified the ANXA1 protein expression in arbitrary units (a.u.) by determining the median optical density (MOD). The results are presented as the means ± SEM.
*p < 0.05 for cancer versus epithelium.
## p < 0.01; ### p < 0.001 for HPV + versus HPV-.
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ship between this reduction and a lack of differentiation in
the tumors [42-45]. To the best of our knowledge, the
present study is the first to evaluate the expression of
ANXA1 in association with HPV infection in oropharyn-
geal cancer, thereby demonstrating a relationship between
two important and current markers for this disease.
Recently, a study was published evaluating protein and
mRNA expression of ANXA1 in relation to the HPV status
in patients with squamous cell carcinoma of the penis [46].
This study demonstrated an increase in ANXA1 expression
in HPV+ carcinomas compared to the expression detected
in HPV- carcinomas. The authors’ proposed hypothesis
was that the E6 viral oncoprotein may induce ANXA1 ex-
pression, an idea that had been suggested in a previous
study [47]. In the present study, we observed an increase in
ANXA1 expression in HPV+ cases compared to HPV-
cases only in normal epithelium of the tumor margin. This
finding suggests the possibility that ANXA1 expression
may be induced by the E6 protein as a precursor event
prior to the malignant conversion of the infected cell. This
inducer effect of ANXA1 expression may be lost in a clearly
neoplastic cell from oropharyngeal site. However, we have
not tested directly the normal epithelium for HPV, but the
cancer counterpart. Therefore, this conclusion is based on
indirect evidence of HPV presence and on the concept of
“field cancerization” [48].
Because ANXA1 is a substrate for protein kinase C
(PKC) and for various tyrosine kinases such as EGFR [49],
it is subject to phosphorylation of amino acid residues, a
process that can confer various biological activities on the
protein [28,29]. PKC executes the phosphorylation of
ANXA1 in the serine 27 residue (ANXA1-SER), which is
linked to the anti-inflammatory effects of the protein [30].
A study using an experimental model of endotoxemiaTable 3 Expression of the phosphorylated forms of ANXA1
ANXA1-SER
HPV+ HPV- Contro
Cancer 13.5 ± 1.6 14.6 ± 0.4 -
Epithelium 23.2 ± 1.7* 16.0 ± 1.0 15.3 ±
The results are described as the means ± SEM.
*p < 0.05 for epithelium versus cancer.
**p < 0.01 for epithelium versus cancer.induced by bacterial lipopolysaccharides demonstrated an
early rise in the level of ANXA1-SER in response to inflam-
matory stimuli [22]. In contrast, phosphorylation of tyro-
sine 21 (ANXA1-TYR) by EGFR and by other tyrosine
kinases is related to the process of cell proliferation. A
study showed that both the expression of ANXA1 and the
phosphorylation of the protein at tyrosine 21 are increased
in the liver during the development of mouse embryos and
decreases after birth. It returns to an elevated state follow-
ing partial hepatectomia [31]. These changes suggest that a
relationship exists between tyrosine 21 phosphorylation,
proliferation of hepatocytes and regeneration of the liver.
Moreover, studies have demonstrated a co-localization be-
tween ANXA1 and of EGFR both in the cell membrane
and in the cytoplasm [50], again attesting to an interaction
between these two markers.
In the present study, we determined that the expression
of ANXA1-SER was increased in the normal epithelia com-
pared to carcinomas in the HPV+ cases. This difference
was not observed in the HPV- cases. The increased expres-
sion in the normal HPV+ tissue compared to in the
HPV+ tumors may indicate a physiological response to the
inflammatory process generated by the viral infection. This
response could be lost in cancer through unknown mecha-
nisms that inactivate this regulatory pathway. Another pos-
sible explanation is the capacity of the tumor to escape
antitumor immunological mechanisms (immune evasion),
with a consequent reduction in immunological and inflam-
matory aggression and in the need to modulate this inflam-
mation. The immune evasion process is well known in
various neoplasms [51] including cancers of the head and
neck [52]. The absence of an increase in ANXA1-SER in
the HPV- epithelium samples compared to the HPV-
carcinoma tissues probably arises from the absence of an
inflammatory reaction to the viral infection.ANXA1-TYR
ls HPV+ HPV- Controls
15.3 ± 0.6** 13.6 ± 1.6* -
0.3 22.2 ± 0.7 18.5 ± 1.5 26.7 ± 0.9
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TYR in cancers compared to the epithelia in both the
HPV + and HPV- samples, a finding that contrasts with
the data reported in a recent study of squamous cell car-
cinoma of the cervix [27]. The reduction in ANXA1-
TYR in oropharyngeal cancer was independent of HPV
status, which may reflect the use of the protein by EGFR
in the process of inducing cell proliferation independent
of whether the etiology of the tumor involves the virus
or not. During signaling for cell proliferation, EGFR is
known to become internalized into the cell, where it in-
teracts with and phosphorylates ANXA1 to produce
ANXA1-TYR; the resulting EGFR-ANXA1-TYR com-
plex subsequently translocates to multivesicular bodies
[26]. We recognize that further studies are needed to
explore these findings.
To better understand both the participation of p53 in car-
cinogenesis of the oropharynx and the relationship between
p53 and ANXA1 and HPV, we evaluated p53 expression by
immunofluorescence. Nuclear positivity for p53 staining
denotes mutation of the TP53 gene or other changes that
inactivate and stabilize the protein [53]. Such immunostain-
ing is generally identified only in cancers or dysplastic tis-
sues [18,54]. Studies have indicated the existence of a
binding site for p53 in the promoter for the ANXA1 gene,
inducing its expression [55]. Our study, however, did not
indicate an increase in the expression of ANXA1 in the
p53+ samples compared to in the p53- ones.
However, we did observe a reduction in the expression
of p53 in HPV + tumors compared to in HPV- ones. The
E6 and E7 oncoproteins produced by high-risk serotypes
of the HPV virus can inactivate the molecular mecha-
nisms that control the cell cycle and apoptosis. Specific-
ally, the E6 protein is able to degrade p53 and to
interact with the pro-apoptotic proteins Bax and Bak, in-
activating these mechanisms of protection against car-
cinogenesis [56]. Therefore, the presence of low levels of
p53 in the HPV + tumors might mean either that an
alternative mechanism that does not involve mutation
exists for inactivating p53 in these tumors or that the
protein is hypoexpressed even in tumors with mutation.
In the latter case, the mutated p53 could possibly have
been degraded and, therefore, did not accumulate in the
cells. Westra et al. observed a reduction in the occur-
rence of mutations in the p53 gene in HPV + tumors of
the head and neck. In addition, they demonstrated that
mutations that were found did not affect the transactiva-
tion site of the p53 protein, suggesting that carcinogen-
esis mediated by HPV is independent of p53 mutation,
even in cases in which a mutation is present [57].
Conclusions
Our findings confirm the presence of the HPV genome
in a substantial proportion of oropharyngeal tumors, aswell as a reduction in the expression of p53 in HPV+ tu-
mors. We also observed a reduction in the expression of
ANXA1 in these tumors in comparison to non-neoplastic
epithelia. We did not observe a relationship between the
expression of ANXA1 or its phosphorylated forms and the
presence of HPV in oropharyngeal cancer. However, our
data suggest that, in non-neoplastic epithelium, ANXA1 ex-
pression is increased in individuals whose tumor is positive
for HPV. The importance of ANXA1 to cancers of the head
and neck is becoming more apparent, and larger studies
are essential to increase our understanding of the participa-
tion of this protein in oropharyngeal carcinogenesis.
Methods
Patients
We obtained samples from 22 patients with previously
untreated oropharyngeal cancer diagnosed at Mato
Grosso Cancer Hospital – Cuiabá/Brazil. The samples
were derived from tumor biopsies and from products of
surgical resections of tumors with non-neoplastic epithe-
lium at the tumor margins. These samples were used to
make comparisons between tumor and non-tumor tis-
sues. In addition, we used 5 samples of epithelial tissue
obtained from the oropharynx of people who had died
from other causes and who did not have head or neck
cancers. We asked all of the study participants or their
family members to read and sign a free and clarified
consent form. The study was approved by the Ethics
Committee of the Federal University of Mato Grosso
(Case 973/CEP-HUJM/2010).
Histopathological analysis
We prepared 3-μm sections of each sample. The slices
were deparaffinized with xylene, hydrated with alcohol
solutions of decreasing concentrations and stained with
hematoxylin-eosin. A medical pathologist then analyzed
the material to confirm the presence of normal epithe-
lium and/or neoplasia and to evaluate the grade of histo-
logical differentiation of each tumor according to the
World Health Organization classification system [58].
Determination of the presence of HPV DNA via
chromogenic in situ hybridization (CISH)
To analyze the presence of HPV genetic material, we used
the Rembrandt® hybridization and detection kit (PanPath,
Budel, Netherlands) according to the manufacturer’s in-
structions. This kit includes two sets of probe mixtures.
One can identify the presence of HPV serotypes 16 and
18, while the other one targets serotypes 31 and 33.
Formalin-fixed, paraffin-embedded samples were sec-
tioned into 4-μm slices with a Hyrax M60 microtome
(Zeiss, Germany) and heated at 56-60°C for 2 h. Next,
we deparaffinized the sections in xylene (2 baths),
dehydrated them in 100% ethanol for 5 minutes, and
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proteolytic treatment with diluted pepsin in 0.1 N HCl
(1:100) for 30 minutes, followed by dehydration in ris-
ing concentrations of ethanol. The denaturation step
involved applying 20 μL of probe solution to each slice,
covering the slices with coverslips sealed with silicon,
and heating them at 95°C for 5 minutes. Next, we incu-
bated the material at 37°C in a wet chamber for 12 to
16 hours to allow hybridization to occur. We then
removed the coverslips by immersing the slides in tris-
buffered saline (TBS). We performed the detection
step by incubating the slides in a solution containing
horseradish peroxidase (HRP) for 30 minutes and then
amplifying the signal by incubation with a 3-amino 9-
ethylcarbazol (AEC) substrate for 5 to 15 minutes. Finally,
we counter-dyed the slides with Methyl Green. The same
reactions were performed with a cervical cancer cell line
(CasKi) that contains the HPV 16 genome, provided by the
manufacturer, as a positive control.
Immunofluorescence analysis of the protein expression of
p16, p53, ANXA1, ANXA1-SER, and ANXA1-TYR
We obtained histological sections of 3-μm thickness and
placed them onto slides with a biological adhesive. After
deparaffinization with xylene, we hydrated the sections
in solutions containing decreasing concentrations of al-
cohol and incubated them in a bain-marie at 70°C in a
0.21% sodium citrate solution (pH = 6.0) for 1 hour.
Next, we treated the cuts with 3% hydrogen peroxide in
70% methanol for 30 minutes to block tissue peroxidase.
To induce permeabilization, we incubated the slides in
0.4% Tween 20 in PBS for 15 minutes and blocked them
for 30 minutes with 5% bovine serum albumin (BSA)
(Sigma-Aldrich, Rio de Janeiro, Brazil), diluted in PBS.
The samples from each patient were then incubated with
the following primary antibodies in 1% BSA for 18 hours
at 4°C in a humidified chamber: mouse anti-p16 (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) at a dilution
of 1:200; rabbit anti-ANXA1 (Invitrogen, Frederick, MD,
USA) and mouse anti-p53 (Invitrogen, Frederick, MD,
USA) together at a dilution of 1:200 for each antibody
(this anti-p53 antibody is capable of identifying both the
wild-type and the mutated forms of the protein); rabbit
anti-ANXA1-SER27 and anti-ANXA1-TYR21 at a dilution
of 1:100 for each antibody [31,59]. Next, the samples were
incubated in secondary goat anti-rabbit antibodies (for
ANXA1 and its phosphorylated forms) and anti-mouse (for
p16 and the dual-stained slides with p53) together with the
fluorochromes ALEXA FLUOR 488 and ALEXA FLUOR
546 (Invitrogen, Eugene, OR, USA) to label the rabbit and
mouse antibodies, respectively (dilution of 1:50 in 1% BSA
for 1 hour at room temperature in a humidified chamber).
We also added the nuclear fluorescent dye 4′,6-diamidino-
2-phenylindole (DAPI), to facilitate the morphologicalidentification of the tissues. The slides were washed in PBS
and mounted in glycerin with PBS (in a 1:1 ratio). We iden-
tified the immunostained cells of the squamous cell carcin-
oma fragments and the non-neoplastic epithelium using
an AxioScope.A1 microscope (Carl Zeiss, Germany). We
quantified the immunoexpression of the ANXA1, ANXA1-
SER, and ANXA1-TYR proteins by median optical density
(MOD) with the aid of image analysis software (Axiovision
v. 4.8.1, 2009) using arbitrary units (a.u.) ranging from 0 to
255. Expression of p16 and p53 was scored as positive or
negative. We compared the expression of ANXA1 in tissues
with and without p53 positivity. For densitometry mea-
sures, images were obtained with a 20× objective lens and
are presented as the average ± SEM based on readings from
5 random sample areas including both the central non-
necrotic area of the tumor and the edge of the tumor
invasion.Statistical analyses
We compared the averages for the various fluorescent
densities using one-way ANOVA with Bonferroni’s post-
test. We used the χ2 method to compare the proportion of
tissues with p53 expression between the HPV+ and HPV-
groups. We used GraphPad Prism v. 5.01 for Windows (La
Jolla, CA, USA) to perform the analyses. P-values below
0.05 were considered to be significant.
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